(Boursier.com) – New blow for DBV Technologies. In large volumes, the title of the company specializing in the treatment of food allergies collapsed by more than 37% to 3 euros at the end of the session. A dropout linked to the latest announcement by the group which asked the European Medicines Agency (EMA) to withdraw its application for marketing authorization for Viaskin Peanut, its flagship experimental treatment for peanut allergy. “DBV’s decision to withdraw the marketing authorization for Viaskin Peanut is the result of careful consideration aimed at submitting the strongest possible application for patients in the European Union,” said Pharis Mohideen, medical director of the group which intends to launch a new phase III study to ultimately obtain the green light from the European and American authorities. What to delay a little more the potential arrival of the product on the market.
© 2021 Boursier.com